Saniona clears obstacle ahead of new trial

The US health authorities have now received the all of the requested documentation for the capsule version of the biotech company's candidate Tesomet. Saniona's plans to begin a clinical trial with the drug before the end of year thus remain unchanged.
Photo: Saniona / PR
Photo: Saniona / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

After dialog with the US Food and Drug Administration (FDA), the biotech company Saniona is sticking to its plans to initiate a phase IIb trial of its drug Tesomet before the end of the year, it reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading